Charles River Laboratories International, Inc. (NYSE:CRL) insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $67.10, for a total transaction of $171,239.20. Following the sale, the insider now directly owns 11,671 shares of the company’s stock, valued at approximately $783,124.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

David Ross Smith also recently made the following trade(s):

  • On Thursday, June 8th, David Ross Smith sold 945 shares of Charles River Laboratories International stock. The shares were sold at an average price of $95.00, for a total transaction of $89,775.00.

Charles River Laboratories International, Inc. (NYSE CRL) traded up 1.12% during midday trading on Wednesday, reaching $99.68. 13,511 shares of the company traded hands. The stock has a market capitalization of $4.74 billion, a P/E ratio of 26.27 and a beta of 1.02. Charles River Laboratories International, Inc. has a 1-year low of $67.20 and a 1-year high of $102.32. The firm has a 50-day moving average of $99.68 and a 200-day moving average of $92.13.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The firm had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. During the same quarter in the previous year, the company posted $1.20 earnings per share. The company’s revenue was up 8.1% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

Charles River Laboratories International announced that its board has approved a share buyback program on Wednesday, May 10th that permits the company to buyback $150.00 million in shares. This buyback authorization permits the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: “Insider Selling: Charles River Laboratories International, Inc. (CRL) Insider Sells 2,552 Shares of Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/16/insider-selling-charles-river-laboratories-international-inc-crl-insider-sells-2552-shares-of-stock.html.

Several equities research analysts have recently commented on CRL shares. Zacks Investment Research lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Jefferies Group LLC reaffirmed a “buy” rating and set a $106.00 price target on shares of Charles River Laboratories International in a research report on Friday, April 21st. Citigroup Inc. reaffirmed a “neutral” rating and set a $104.00 price target (up previously from $90.00) on shares of Charles River Laboratories International in a research report on Thursday, May 11th. BidaskClub lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Barclays PLC reaffirmed a “hold” rating and set a $102.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $96.94.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC boosted its position in shares of Charles River Laboratories International by 0.7% in the fourth quarter. Teachers Advisors LLC now owns 118,195 shares of the medical research company’s stock valued at $9,005,000 after buying an additional 788 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Charles River Laboratories International by 2.6% in the first quarter. Louisiana State Employees Retirement System now owns 12,000 shares of the medical research company’s stock valued at $1,079,000 after buying an additional 300 shares in the last quarter. Columbus Circle Investors boosted its position in shares of Charles River Laboratories International by 170.2% in the first quarter. Columbus Circle Investors now owns 75,724 shares of the medical research company’s stock valued at $6,811,000 after buying an additional 47,703 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Charles River Laboratories International by 12.1% in the first quarter. Acadian Asset Management LLC now owns 901,154 shares of the medical research company’s stock valued at $81,058,000 after buying an additional 97,344 shares in the last quarter. Finally, Cardinal Capital Management boosted its position in shares of Charles River Laboratories International by 1.1% in the first quarter. Cardinal Capital Management now owns 7,035 shares of the medical research company’s stock valued at $633,000 after buying an additional 76 shares in the last quarter. Institutional investors own 93.79% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.